Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-13

Clinical Trial Update: Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dasatinib monotherapy in AML patients refractory to venetoclax-azacitidine; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sprycel (dasatinib)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING